CMV immunoglobulin to prevent disease after transplant
Part of Immune system & allergy, Infections, Kidney & urinary clinical trials.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting a kidney, liver, or both a kidney and liver from a donor who has CMV (a common virus).
- You do not have CMV yourself before the transplant.
- You are between 18 and 75 years old.
- You are willing to have routine blood tests after transplant.
- You have not had a severe reaction to CMV immunoglobulin or other blood products before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This trial tests whether an experimental drug (CMVIG) can prevent CMV infection in kidney transplant patients who are switching to or already on belatacept, a newer immunosuppressant. It may help protect those at higher risk for CMV.
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
This trial tests a special machine that washes a donated kidney with a drug to remove a common virus called CMV before transplant. It may help prevent the virus from infecting the person who receives the kidney.
Hear when a new Cytomegalovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.